Finanzas de Haemonetics Corp (HAE)HAEHaemonetics Corp

Haemonetics Corp (HAE) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Apheresis, accounting for 56.4% of total sales, equivalent to $191.32M. Another important revenue stream is MedSurg. Understanding this composition is critical for investors evaluating how HAE navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Haemonetics Corp maintains a gross margin of 56.98%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 20.68%, while the net margin is 9.73%. These profitability ratios, combined with a Return on Equity (ROE) of 11.20%, provide a clear picture of how effectively HAE converts its operational activities into shareholder value.

In the context of the broader market, HAE competes directly with industry leaders such as LIVN and ICUI. With a market capitalization of $4.69B, it holds a leading position in the sector. When comparing efficiency, HAE's gross margin of 56.98% stands against LIVN's 70.07% and ICUI's 42.61%. Such benchmarking helps identify whether Haemonetics Corp is trading at a premium or discount relative to its financial performance.

Haemonetics reported Q2 revenue of $339.4 million, exceeding analyst expectations and reflecting a 5.6% year-on-year growth. The gross margin is strong at 54.22%, and the forward P/E ratio is 20.28, indicating reasonable valuation relative to future earnings.